Value and Access Advisor at Schoonveld Advisory, LLC and columnist for Pharmaceutical Commerce
Strategies in Today’s Market for Pricing and Reimbursement Models
July 14th 2025A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.
Challenges for Bringing Orphan Drugs to Market
July 9th 2025Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.
Harmonizing the Payer Perspective with Real-World Evidence
July 7th 2025Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.
Effective Real-World Evidence for Adding Value to a Clinical Trial
June 30th 2025In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.
Navigating Regulatory Barriers within Market Access
June 25th 2025A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.
Industry Voices on Current Pricing and Reimbursement Models
June 23rd 2025Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.